PropertyValue
is ?:annotates of
?:authorAffiliation
  • [\'Vir Biotechnology, San Francisco, CA, USA. aarvin@vir.bio.\', \'Stanford University School of Medicine, Stanford, CA, USA. aarvin@vir.bio.\', \'Vir Biotechnology, San Francisco, CA, USA.\', \'Humabs Biomed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland.\', \'Vir Biotechnology, San Francisco, CA, USA. svirgin@vir.bio.\', \'Washington University School of Medicine, Saint Louis, MO, USA. svirgin@vir.bio.\']
?:citedBy
  • -1
?:creator
?:doi
?:doi
  • 10.1038/s41586-020-2538-8
?:hasPublicationType
?:journal
  • Nature
is ?:pmid of
?:pmid
?:pmid
  • 32659783
?:publication_isRelatedTo_Disease
?:rankingScore_SJR
  • 17.875
?:rankingScore_hIndex
  • 1052
is ?:relation_isRelatedTo_publication of
?:title
  • A perspective on potential antibody-dependent enhancement of SARS-CoV-2.
?:type
?:year
  • 2020

Metadata

Anon_0  
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://purl.org/net/provenance/ns#DataItem>
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://www.w3.org/2004/03/trix/rdfg-1/Graph>
<http://xmlns.com/foaf/0.1/primaryTopic> <https://research.tib.eu/covid-19/entity/32659783>
<http://xmlns.com/foaf/0.1/topic> Anon_0
<http://www.ontologydesignpatterns.org/cp/owl/informationrealization.owl#realizes> <https://research.tib.eu/covid-19/data/entity/32659783>
<http://purl.org/net/provenance/ns#createdBy>
Anon_1   (more)
expand all